UA127588C2 - Способи застосування та композиції, які містять дулаглутид - Google Patents

Способи застосування та композиції, які містять дулаглутид Download PDF

Info

Publication number
UA127588C2
UA127588C2 UAA202002355A UAA202002355A UA127588C2 UA 127588 C2 UA127588 C2 UA 127588C2 UA A202002355 A UAA202002355 A UA A202002355A UA A202002355 A UAA202002355 A UA A202002355A UA 127588 C2 UA127588 C2 UA 127588C2
Authority
UA
Ukraine
Prior art keywords
dulaglutide
dose
subject
weeks
once
Prior art date
Application number
UAA202002355A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дейвід Ендрю Кокс
Дэйвид Эндрю Кокс
Звонко Мілішевіч
Звонко Милишевич
Лай Сань Зем
Ендрю Гордон Уернер
Эндрю Гордон Уэрнер
Дейвід Бредлі Вудворд
Дэйвид Брэдли Вудворд
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA127588(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA127588C2 publication Critical patent/UA127588C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
UAA202002355A 2017-11-21 2018-11-13 Способи застосування та композиції, які містять дулаглутид UA127588C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Publications (1)

Publication Number Publication Date
UA127588C2 true UA127588C2 (uk) 2023-10-25

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202002355A UA127588C2 (uk) 2017-11-21 2018-11-13 Способи застосування та композиції, які містять дулаглутид

Country Status (21)

Country Link
US (2) US11576950B2 (enExample)
EP (1) EP3713593A2 (enExample)
JP (3) JP7221956B2 (enExample)
KR (2) KR20220146656A (enExample)
CN (2) CN120478602A (enExample)
AU (2) AU2018372709B2 (enExample)
BR (1) BR112020007817A2 (enExample)
CL (1) CL2020001252A1 (enExample)
CR (1) CR20200202A (enExample)
DO (1) DOP2020000104A (enExample)
EA (1) EA202090971A1 (enExample)
EC (1) ECSP20026436A (enExample)
IL (1) IL274563B2 (enExample)
JO (1) JOP20200126A1 (enExample)
MA (1) MA50798A (enExample)
MX (1) MX2020005231A (enExample)
PE (1) PE20200847A1 (enExample)
PH (1) PH12020550795A1 (enExample)
SG (1) SG11202003687RA (enExample)
UA (1) UA127588C2 (enExample)
WO (1) WO2019103875A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
AU2021213682B2 (en) * 2020-01-30 2025-05-29 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4153130A1 (en) * 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
CA3223313A1 (en) 2021-06-23 2022-12-29 Eli Lilly And Company Methods of using and compositions including an incretin analog

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
CN101044162B (zh) 2004-12-22 2010-10-27 伊莱利利公司 Glp-1类似物融合蛋白质制剂
BRPI0813699B1 (pt) * 2007-07-10 2021-06-22 Eli Lilly And Company Formulação de proteína de fusão glp-1-fc
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN110650747A (zh) 2017-06-01 2020-01-03 伊莱利利公司 用于治疗慢性肾病的杜拉鲁肽

Also Published As

Publication number Publication date
CN111356472A (zh) 2020-06-30
US11576950B2 (en) 2023-02-14
JP2021502379A (ja) 2021-01-28
JOP20200126A1 (ar) 2020-05-21
IL274563A (en) 2020-06-30
US20240189394A1 (en) 2024-06-13
SG11202003687RA (en) 2020-06-29
JP7221956B2 (ja) 2023-02-14
EP3713593A2 (en) 2020-09-30
AU2022203372A1 (en) 2022-06-09
MX2020005231A (es) 2020-08-24
AU2018372709A1 (en) 2020-05-14
ECSP20026436A (es) 2020-06-30
KR20220146656A (ko) 2022-11-01
EA202090971A1 (ru) 2020-08-07
WO2019103875A2 (en) 2019-05-31
CN120478602A (zh) 2025-08-15
PH12020550795A1 (en) 2021-04-19
DOP2020000104A (es) 2020-08-31
IL274563B1 (en) 2023-08-01
NZ763815A (en) 2023-11-24
BR112020007817A2 (pt) 2020-10-06
AU2022203372B2 (en) 2025-04-10
WO2019103875A3 (en) 2019-07-25
JP2024056908A (ja) 2024-04-23
US20200330558A1 (en) 2020-10-22
KR102589234B1 (ko) 2023-10-16
CR20200202A (es) 2020-08-20
JP2022062153A (ja) 2022-04-19
PE20200847A1 (es) 2020-08-18
CL2020001252A1 (es) 2020-10-30
MA50798A (fr) 2020-09-30
CA3082625A1 (en) 2019-05-31
AU2018372709B2 (en) 2022-04-28
KR20200076705A (ko) 2020-06-29
IL274563B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
US11896567B2 (en) Combination composition
UA127588C2 (uk) Способи застосування та композиції, які містять дулаглутид
CN107496907A (zh) 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品
JP2019501886A5 (enExample)
US20110218206A1 (en) Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
AU2021391951A9 (en) Treatment of hemophilia with fitusiran
RU2015117995A (ru) Композиции и способы лечения эктодермальной дисплазии
EP3258935B1 (en) Iloperidone for the treatment of schizophrenia
WO2012005605A1 (en) A combination composition comprising ibuprofen and paracetamol
CA3082625C (en) Methods of using and compositions containing dulaglutide
EA041605B1 (ru) Способы применения и композиции, содержащие дулаглутид
AU2017305856A1 (en) Pharmaceutical formulations of C1 esterase inhibitor
WO2021255438A1 (en) Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome
Gras Berotralstat. Plasma kallikrein (KLKB1) inhibitor, Treatment of hereditary angioedema attacks
Audhya et al. Agreement Between Improvements in Patient Global Impression of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial With Sebetralstat (KVD900) in Patients With Hereditary Angioedema
CA3004348C (en) Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
Patch FDA Drug Approvals
Baker Current FDA-Related Drug Information-New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; New Drug/Biologics License Applications Filed by Manufacturer; Significant Labeling Changes or'Dear Health Professional'Letters Related to Safety
Khan et al. What are the current therapeutic options for haemorrhagic strokes?